Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
about
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancerMolecular Technologies in the Clinical Diagnostic LaboratoryMicrofluidic enrichment for the single cell analysis of circulating tumor cells.Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoringGuide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancerLiquid biopsy genotyping in lung cancer: ready for clinical utility?Meta-analysis of the impact of de novo and acquired EGFR T790M mutations on the prognosis of patients with non-small cell lung cancer receiving EGFR-TKIs.Dynamic monitoring of EGFR mutations in circulating cell-free DNA for EGFR-mutant metastatic patients with lung cancer: Early detection of drug resistance and prognostic significanceNext-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients.Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutationComparison of EGFR mutation status between plasma and tumor tissue in non-small cell lung cancer using the Scorpion ARMS method and the possible prognostic significance of plasma EGFR mutation statusClinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutationsDigital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer.Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet?Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patientsCirculating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistanceDetection of the T790M mutation of EGFR in plasma of advanced non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study)Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS geneAZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trialsPrognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma.c-Met inhibition enhances chemosensitivity of human ovarian cancer cells.Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Liquid Biopsy in Non-Small Cell Lung Cancer.The liquid biopsy in lung cancerMicroRNA-21 versus microRNA-34: Lung cancer promoting and inhibitory microRNAs analysed in silico and in vitro and their clinical impact.Molecular methods (digital PCR and real-time PCR) for the quantification of low copy DNA of Phytophthora nicotianae in environmental samples.Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan.Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA.Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
P2860
Q26741318-4777A04F-10EA-4998-B6E8-E0D47916DE4DQ26741814-54F28371-991D-4B8E-B12C-1244A11EF447Q26775376-44AED3C8-4D0F-4217-BEC0-7568FF26D9B5Q26996463-F7A344AA-01A6-487D-B99F-7BD37AFDE9F0Q27340255-961119E9-96CA-4AC9-BEE2-C7CCFA47559BQ28076191-0785C158-E21E-4C74-B9EC-3D10287CDE85Q28079253-5F74DA88-A199-44A5-92AF-5B485D5B4EA1Q33567037-58A585D0-66BE-4744-9AE6-EB9E4FD23D61Q33621143-3A227B23-FAAE-4461-854E-67AFB80F1C2DQ33751216-A819D7F3-FC21-4178-A8FD-4C50E0918E4AQ35842446-A9E47E4E-A10B-468E-BD6D-A4CB63A38440Q36104839-852F495D-C1A8-414D-9C61-10B6FD0B9E2AQ36276264-FED8F957-D2E5-425D-A59B-D47C37A26B64Q36375343-AABA5C32-1A59-4D21-B23C-C86204B5263CQ36477762-ACB21296-4101-46CA-8FD0-C20218D50BAAQ36544438-C2A36DE3-1CA1-4F45-B6CA-E869A1B87051Q36715107-37B1163B-CE11-4805-83A9-F76265617F73Q37160293-CBC6839A-F156-43ED-A861-1773D214E88AQ37242412-CB632B09-61C2-42C2-84AF-2CBD4B6980CAQ37264652-AFB55216-5DC0-4610-BE38-A4350BC3F219Q37536958-71F0DBAE-D784-406C-89CB-D8F0E25ED246Q37609221-917F924D-7E13-413A-83A6-F132BD3E3A0DQ37629050-35382303-A32E-4EE5-B8DD-B94793BA813EQ37701499-C36C1C11-DD11-466A-8733-6DEF699E31EEQ37706284-04841A0B-E453-418F-841D-43CECE44BF39Q38373863-BEE46D08-9DB3-419A-97C2-F22216B556B0Q38549733-14B26207-CDC9-4DD1-AF83-516A1C278859Q38584814-DEF90995-6A12-487B-941F-55FCCB1FB7F6Q38694431-BFBB7A8D-C6DE-4288-AD59-237082A34DDCQ38744357-7EE710B6-BAB4-4DCA-A0A3-5A4FA7F976F7Q38844281-6986BF29-B768-40BC-A518-C3E8749B5277Q39076207-B26744C7-FFE3-4BB4-B49B-2678F0A472F2Q39132753-A99FFC04-DF05-46C4-B590-DAC4BC656881Q39433270-8D832424-9D47-4C8B-B820-DB2A0532B90CQ40283315-AA9DE11B-A2C0-4B1A-8422-308BAEA5B54EQ40393934-02828B48-A4B3-416D-885D-E7E9BA337D01Q40502030-88B52F17-7906-416F-BEE5-BD1E7F0C6DA8Q40570622-F48E5316-18C2-4C9E-9627-4BBFCC6B0ACFQ41932233-8A0D3856-AB5A-465A-903C-64D2681B4A70Q42835050-C783BF57-EC01-4925-9A38-72253FA13F06
P2860
Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@ast
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@en
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@nl
type
label
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@ast
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@en
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@nl
prefLabel
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@ast
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@en
Quantification and dynamic mon ...... I treatment in advanced NSCLC.
@nl
P2093
P2860
P1433
P1476
Quantification and dynamic mon ...... KI treatment in advanced NSCLC
@en
P2093
Jianchun Duan
Shuhang Wang
Tongtong An
Yuyan Wang
P2860
P304
P356
10.1371/JOURNAL.PONE.0110780
P407
P50
P577
2014-11-18T00:00:00Z